Perfectus Biomed Limited are excited to officially announce that our merger with Wyoming based laboratory, Extherid Biosciences, has now been completed. The merger has seen the creation of Perfectus Biomed Group with two operating subsidiaries.
Effective 1st June 2020, Extherid Biosciences will be known as Perfectus Biomed LLC and the UK subsidiary will continue to be known as Perfectus Biomed Limited.
The merger brings together a breadth of industry experience and expands our service offering and geographical reach. Prior to the merger both CROs focused on customised testing that supported their client’s product development and regulatory journeys. Clients with multinational needs requiring such support will continue to receive the quality they have come to know and expect from Perfectus Biomed but with added expertise in both geographies, increasing testing capabilities.
In the U.K. services are UKAS accredited and GLP compliant and ISO 9001 certified. Specialist services include accredited biofilm testing, microbiology, molecular biology, cell culture and virology. These services are used to support companies in medical device, wound care, biocide, cosmetic and pharmaceutical sectors.
The U.S. facility’s expertise lies in experimental therapeutics and preclinical infectious disease research, through customisable tissue models. The facility provides specialist research for the medical device, urogenital health, wound care, inflammation and biocompatibility sectors.
Dr Samantha Westgate PhD, CEO of Perfectus Biomed Group explains; “We are delighted to be merging with Extherid Biosciences and look forward to offering our clients an enhanced service and an expanded geographical offering”.
The merger will drive continued growth plans over the coming months and years with development opportunities arising for existing staff as well as creating recruitment opportunities to support our target sectors.
To keep up to date with Perfectus Biomed Group’s international developments please visit our website, www.perfectusbiomed.com, follow our activities on social media or reach out to our teams via info@perfectusbiomed.com.
© UKI2S and Future Planet Capital (Ventures) Limited. All Rights Reserved. UKI2S is managed by Future Planet Capital (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England and Wales. Company Number 2500898. Registered Address: Future Planet Capital (Ventures) Limited, 1 Scott Place, 2 Hardman Street, Manchester, M3 3AA.
